Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods and compositions for modulating AAV infection

a technology of aav infection and composition, applied in the field of methods and compositions for modulating aav infection, can solve the problems of poorly understood basic aspects of aav cellular entry, and achieve the effects of reducing increasing the level, and enhancing the permissiveness of the target cell

Active Publication Date: 2020-04-28
OREGON HEALTH & SCI UNIV +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach enables the modulation of AAV infection efficacy and tropism by altering AAVR expression or affinity, making cells more or less permissive to AAV, facilitating effective nucleic acid delivery and identifying AAV variants with enhanced or reduced infection efficiency.

Problems solved by technology

Considerable efforts are made to engineer AAV variants with novel and biomedically valuable cell tropisms to allow efficacious systemic administration, yet basic aspects of AAV cellular entry are still poorly understood.
For example, in some cases, a target cell can be one that is very difficult to transfect with AAV (i.e., the cell exhibits low permissiveness to AAV infection), and such methods can render such cells permissive to AAV infection.
For example, in some cases, a target cell can be one that is very difficult to transfect with AAV (i.e., the cell exhibits low permissiveness to AAV infection), and such methods can render such cells permissive to AAV infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for modulating AAV infection
  • Methods and compositions for modulating AAV infection
  • Methods and compositions for modulating AAV infection

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0341]An unbiased, haploid genetic screen was performed to identify critical players in AAV serotype 2 (AAV2) infection. The most significantly enriched gene of the screen encodes a type-I transmembrane protein, KIAA0319L (hereafter referred to as “adeno-associated virus receptor” or “AAVR”). The experiments disclosed herein show that AAVR is a protein capable of rapidly endocytosing from the plasma membrane and trafficking to the trans-Golgi network. The experiments disclosed herein further show that AAVR directly binds to AAV2 particles, and that anti-AAVR antibodies efficiently blocked AAV2 infection, that genetic ablation of AAVR rendered a wide range of mammalian cell types highly resistant to AAV2 infection, and that AAVR serves as a critical host factor for all AAV serotypes tested, including AAV1, 3B, 5, 6, 8 and 9. The importance of AAVR for in vivo gene delivery is demonstrated by the robust resistance of AAVR− / − mice to AAV infection. Collectively, the data presented here...

example 2

[0372]FIG. 14 shows that delivery of AAVR protein (e.g., using AAVR-containing gesicles) can restore AAV infection in HeLa AAVR-KO cells (which are cells knocked out for AAVR, and therefore do not express functional endogenous AAVR protein). “Uninfected” and “WT 293” are negative and positive controls, respectively. “None” is the level of infection observed in AAVR-KO cells (confirming that AAVR is an important receptor for AAV infection). “+gAAVR” is the level of infection observed when AAVR-KO cells are treated with gesicles (VSV-G induced microvesicles) that include AAVR (and AAVR is thereby delivered to the cells). Delivery of exogenous AAVR protein can therefore vastly increase a cell's permissiveness to AAV infection. “+gGFP” is a negative control in which GFP protein (instead of AAVR) is delivered to cells via gesicles. The top bar graph shows % of AAV2 infection on the Y axis while the bottom bar graph MFI (Mean Fluorescence Intensity) measured upon infection with AAV2.

[0373...

example 3

[0374]To validate AAVR's role in AAV2 infection, CRISPR / Cas9 genome engineering was used to generate isogenic AAVR knock-out cell lines (AAVRKO) in a panel of cell types representing various human and murine tissues. FIG. 16 provides data showing that isogenic AAVR knock-out cell lines (AAVRKO) in a panel of cell types representing various human and murine tissues exhibited low permissiveness to infection by AAV2. Moreover, gesicles containing AAVR delivered to the AAVR-KO cells facilitated AAV2 infection. In contrast, as a negative control, gesicles containing GFP did not facilitate AAV2 infection. Thus, AVVR plays a critical role in AAV infection in a variety of different mammalian cell types.

[0375]FIG. 17 provides data showing that overexpression of AAVR enhanced AAV2 and AAV6 infection in K562 cells. Thus, the addition of AAVR to cells increases their permissiveness to AAV infection, and the increased permissiveness is not limited to any particular AAV serotype.

[0376]FIG. 18. Pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
dissociation constantaaaaaaaaaa
Login to View More

Abstract

Compositions and methods are provided for modulating adeno-associated virus (AAV) infection. For example, compositions and methods are provided for enhancing permissiveness of a target cell to AAV infection (e.g., by increasing levels of AAVR (KIAA0319L) in the cell), for reducing permissiveness of a target cell to AAV infection (e.g., by reducing levels of AAVR in the cell), and for nucleic acid delivery (e.g., by (i) increasing permissiveness of a target cell to AAV infection, e.g., by increasing the amount of AAVR in the cell; and (ii) contacting the target cell with an AAV particle that includes a nucleic acid of interest). Also provided are screening methods and kits for practicing the methods of the disclosure.

Description

CROSS REFERENCE[0001]This application is a national stage entry of PCT Application No. PCT / US2016 / 061187, filed Nov. 9, 2016, which claims benefit of U.S. Provisional Patent Application No. 62 / 253,593, filed Nov. 10, 2015, which application is incorporated herein by reference in its entirety.GOVERNMENT RIGHTS[0002]This invention was made with Government support under contracts A1104557 and GM066875 awarded by the National Institutes of Health. The Government has certain rights in the invention.INTRODUCTION[0003]Adeno-associated virus (AAV) vectors are currently the leading candidates for virus-based gene therapy because of their broad tissue tropism, non-pathogenic nature and low immunogenicity. They have been successfully used in clinical trials to treat hereditary diseases such as hemophilia B and have been approved for treatment of lipoprotein lipase deficiency in Europe. Considerable efforts are made to engineer AAV variants with novel and biomedically valuable cell tropisms to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C12N15/113C07K14/705C12N15/86C12N15/85C12N15/62
CPCC07K14/705C12N15/1138C12N15/8509C12N15/113C12N15/86C12N2710/10032C12N2015/8581C12N2310/14C12N15/625C12N2750/14152C12N2330/50C12N2015/859
Inventor PILLAY, SIRIKACARETTE, JANCHAPMAN, MICHAEL STEWARTMEYER, NANCYPUSCHNIK, ANDREASDAVULCU, OMAR
Owner OREGON HEALTH & SCI UNIV